Genomic integrity of human induced pluripotent stem cells: Reprogramming, differentiation and applications

• Published in: World journal of stem cells 2019-10, Vol.11 (10), p.729-747
• Main Authors: Steichen, Clara, Hannoun, Zara, Luce, Eléanor, Hauet, Thierry, Dubart-Kupperschmitt, Anne
• Format: Article
• Language: English
• Subjects: Review
• ISSN: 1948-0210; 1948-0210
• DOI: 10.4252/wjsc.v11.i10.729

Ten years after the initial generation of induced pluripotent stem cells (hiPSCs) from human tissues, their potential is no longer questioned, with over 15000 publications listed on PubMed, covering various fields of research; including disease modeling, cell therapy strategies, pharmacology/toxicology screening and 3D organoid systems. However, despite evidences that the presence of mutations in hiPSCs should be a concern, publications addressing genomic integrity of these cells represent less than 1% of the literature. After a first overview of the mutation types currently reported in hiPSCs, including karyotype abnormalities, copy number variations, single point mutation as well as uniparental disomy, this review will discuss the impact of reprogramming parameters such as starting cell type and reprogramming method on the maintenance of the cellular genomic integrity. Then, a specific focus will be placed on culture conditions and subsequent differentiation protocols and how their may also trigger genomic aberrations within the cell population of interest. Finally, in a last section, the impact of genomic alterations on the possible usages of hiPSCs and their derivatives will also be exemplified and discussed. We will also discuss which techniques or combination of techniques should be used to screen for genomic abnormalities with a particular focus on the necessary quality controls and the potential alternatives.